Xenetic Biosciences (NASDAQ:XBIO) Given Neutral Rating at HC Wainwright

Xenetic Biosciences (NASDAQ:XBIO)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a report issued on Thursday,Benzinga reports. HC Wainwright also issued estimates for Xenetic Biosciences’ Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Xenetic Biosciences Stock Down 0.9 %

Shares of XBIO stock opened at $3.37 on Thursday. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.20. The business’s 50 day moving average is $3.98 and its two-hundred day moving average is $3.99. The company has a market cap of $5.20 million, a PE ratio of -1.27 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.48). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.18 million. As a group, equities analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC increased its position in Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,550 shares of the company’s stock after purchasing an additional 9,700 shares during the quarter. Renaissance Technologies LLC owned approximately 1.66% of Xenetic Biosciences worth $102,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.